Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Postprint
DOI
 |
Open Access Green |
as soon as is submitted to ZB.
Früherkennung und Primärprävention des Typ-1-Diabetes: „Global Platform for the Prevention of Autoimmune Diabetes“ (GPPAD).
Early detection and primary prevention of type 1 diabetes: Global Platform for the Prevention of Autoimmune Diabetes (GPPAD).
Diabetologie 14, 240-244 (2018)
Background: Betacell autoimmunity, which leads to type 1 diabetes, starts in early childhood with a peak in incidence at 12 months and insulin is its primary target. GPPAD (Global Platform for the Prevention of Autoimmune Diabetes): This network of collaborating European scientists aims to realize the early detection of an elevated risk to develop type 1 diabetes and primary prevention of betacell autoimmunity and type 1 diabetes in Europe. A new genetic risk score can identify newborns with 25-fold increased risk of type 1 diabetes. These children can participate in a primary prevention trial called POInT (Primary Oral Insulin Trial). POInT study: This is a randomized, placebo-controlled, double-blind clinical trial that will test the efficacy of oral insulin to prevent autoimmunity and type 1 diabetes.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Autoimmune Diabetes ; Genetic Predisposition To Disease ; Genetic Testing ; Infant, Newborn ; Insulin; Cell-line Thp-1; In-vitro; Hacat Keratinocytes; Alkaloid Berberine; Dendritic Cells; Injury; Skin; Sensitization; Expression; Toxicity
ISSN (print) / ISBN
2731-7447
e-ISSN
2731-7455
Journal
Diabetologie, Die
Quellenangaben
Volume: 14,
Issue: 4,
Pages: 240-244
Publisher
Springer
Publishing Place
Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes Research Type 1 (IDF)